サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1510744

北米の経皮ドラッグデリバリーシステム市場：2030年予測と地域別分析- タイプ別、用途別、流通チャネル別

North America Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel

出版日
ページ情報
英文 109 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
北米の経皮ドラッグデリバリーシステム市場：2030年予測と地域別分析- タイプ別、用途別、流通チャネル別
出版日: 2024年05月07日
発行: The Insight Partners
ページ情報: 英文 109 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の経皮ドラッグデリバリーシステム市場は、2022年の149億7,762万米ドルから2030年には209億5,837万米ドルに成長すると予測されています。2022年から2030年までのCAGRは4.3%と推定されます。

慢性疾患の増加が北米の経皮ドラッグデリバリーシステム市場を牽引

狭心症、アテローム性動脈硬化症、狭心症、急性心筋梗塞などの心血管疾患（CVD）は、世界における一般的な死亡原因のひとつです。WHOによると、CVDは世界中で毎年1,790万人が死亡する主な原因となっています。CVDの治療薬として多くの医薬品が市販されているが、従来のカプセルや錠剤では病気を効果的に抑えることができないです。このため、薬物のバイオアベイラビリティを延長し、心血管系の患部に標的を絞ったドラッグデリバリーシステムが必要とされています。経皮ドラッグデリバリーシステムは、心血管疾患の治療において、通常の経口投与薬よりも多くの利点を提供します。薬物粒子を包含する経皮パッチは皮膚表面に適用されます。心臓パッチは、細胞生着改善のための優れたプラットフォームを提供します。例えば、最近開発された血管化心臓パッチは虚血性心損傷の治療に有望な可能性を示しています。ニトログリセリン経皮パッチは、冠動脈疾患患者の狭心症（胸痛）エピソードを予防するために使用されます。このパッチは血管を弛緩させ、心臓への負担を軽減し、酸素の必要性を低下させる。しかし、このパッチはすでに始まっている狭心症発作の治療には使えないです。

アルツハイマー病協会の報告によると、2019年、アルツハイマー病は米国における主要死因の第6位、2020年と2021年には第7位にランクされました。米国国立衛生研究所の2023年の統計によると、65歳以上のアメリカ人は670万人（つまり9人に1人、人口の10.8％）がアルツハイマー型認知症です。アルツハイマー型認知症の人の割合は年齢とともに増加します。65～74歳の5％、75～84歳の13.1％、85歳以上の33.3％がアルツハイマー型認知症です。2021年に発表された"Global Prevalence of Young-Onset Dementia "報告書によると、米国における若年発症認知症の有病率は、30～64歳の人口10万人あたり110人、米国人全体では～20万人と推定されています。リバスチグミン貼付剤は、軽度、中等度、重度のアルツハイマー型認知症やパーキンソン病に伴う軽度から中等度の認知症に伴う認知症（物忘れ）の治療に使用されます。リバスチグミンとドネペジルは用量反応関係を示すコリンエステラーゼ阻害薬であり、高用量ほど高い効果を示します。リバスチグミンは親油性で親水性の小さな分子であり、化学的に経皮投与に適しています。

糖尿病は生命を脅かす慢性疾患で、特効薬はないです。いずれのタイプの糖尿病も、身体の様々な部位に様々な問題を引き起こし、早死にのリスクを高める。国際糖尿病連合（IDF）の糖尿病アトラス第10版の報告によると、2021年には世界全体で5億3,700万人の成人（20～79歳）が糖尿病であり、その数は2030年には6億4,300万人、2045年には7億8,300万人に達すると見られています。糖尿病管理には通常、外因性インスリンを皮下投与します。しかし、最近では、必要なときにインスリンを投与するスマートパッチが注目されており、インスリン摂取を簡便化し、標的作用を活性化することができます。

このように、心血管疾患、アルツハイマー病、糖尿病などの慢性疾患の増加が経皮ドラッグデリバリーシステム市場の成長を後押ししています。

北米の経皮ドラッグデリバリーシステム市場概要

北米の経皮ドラッグデリバリーシステム市場は、米国、カナダ、メキシコに区分されます。2022年には、米国が北米の経皮ドラッグデリバリーシステム市場で最大のシェアを占めました。経皮ドラッグデリバリーシステムにおける技術革新の進展と中枢神経系疾患の増加は、予測期間中に北米の経皮ドラッグデリバリーシステム市場の成長を加速させると予測される数少ない要因の一つです。さらに、研究開発活動の増加と新製品のイントロダクションが経皮ドラッグデリバリーシステム市場を促進しています。米国心臓協会（AHA）によると、心血管疾患（CVD）は依然として米国における死亡原因の第1位です。CDCによると、2021年にはCVDによる死亡者数は69万5,000人に達し、米国の死亡者数の5人に1人がCVDで死亡しています。心血管疾患、糖尿病、慢性疼痛状態、その他の慢性疾患の有病率の上昇は、効果的で利便性の高い治療オプションに対する需要を促進しています。医療用パッチは、非侵襲的で患者に優しいアプローチを提供し、薬物を投与してこれらの慢性疾患に関連する症状を管理します。ウェアラブル・センサやフレキシブル・エレクトロニクスなど、TDDSの継続的な進歩が経皮ドラッグデリバリーシステム市場の成長に寄与しています。これらの進歩により、より正確な投与、患者モニタリングの強化、患者のコンプライアンス向上が可能になります。2021年にBiomaterials Researchが発行した「Recent advances in transdermal drug delivery systems（経皮ドラッグデリバリーシステムの最近の進歩）」と題する報告書によると、マイクロニードルはTDDSモダリティの中でも大きな注目を集めており、マイクロニードルの利点を組み合わせることで既存の単純な塗布タイプやパッチタイプのニードルの限界を克服し、より高い治療効率と効果を得ることができます。これらのTDDSの進歩は、心血管疾患や中枢神経系疾患、糖尿病、神経筋疾患、感染症や局所感染症などの蔓延を抑制する原動力となり得る。

個々の患者に合わせて治療を行う個別化医療の動向の高まりが、制御された標的薬物送達を提供する医療用パッチの開発を後押ししています。このカスタマイズにより、患者の転帰が改善され、治療効果が向上します。例えば、2020年、Reddy's Laboratories社は、米国市場でNitroDur（ニトログリセリン）経皮注入システムのオーソライズド・ジェネリック・バージョンを発売しました。在宅ヘルスケアや患者の遠隔モニタリングが重視されるようになる中、医療用パッチは従来のヘルスケア環境以外でも薬剤を投与したりバイタルサインをモニタリングしたりできる便利なソリューションを提供しています。米国の経皮ドラッグデリバリーシステム市場は、慢性疾患の有病率の増加、技術進歩の高まり、個別化医薬品への注目の高まりといった要因の影響を受けています。

北米の経皮ドラッグデリバリーシステム市場の収益と2030年までの予測

北米の経皮ドラッグデリバリーシステム市場のセグメンテーション

北米の経皮ドラッグデリバリーシステム市場は、タイプ、用途、流通チャネル、国に区分されます。

タイプ別では、北米の経皮ドラッグデリバリーシステム市場は、経皮パッチ、経皮ゲル、経皮スプレー、その他に区分されます。2022年の北米の経皮ドラッグデリバリーシステム市場では、経皮ゲル分野が最大のシェアを占めています。経皮パッチはさらに、薬物接着パッチ、マトリックスパッチ、リザーバー膜パッチ、蒸気パッチに細分化されます。

用途別では、北米の経皮ドラッグデリバリーシステム市場は、心血管疾患、中枢神経障害、疼痛管理、ホルモン用途、その他の用途に区分されます。疼痛管理分野は、2022年の北米の経皮ドラッグデリバリーシステム市場で最大のシェアを占めました。疼痛管理はさらにオピオイドと非オピオイドに細分化されます。ホルモン用途は、さらに経皮エストロゲン＆プロゲステロン療法とテストステロン補充に細分化されます。

流通チャネルに基づき、北米の経皮ドラッグデリバリーシステム市場は病院薬局、小売薬局、オンライン薬局、その他に区分されます。2022年の北米の経皮ドラッグデリバリーシステム市場では、病院薬局セグメントが最大のシェアを占めています。

国別では、北米の経皮ドラッグデリバリーシステム市場は米国、カナダ、メキシコに区分されます。2022年の北米の経皮ドラッグデリバリーシステム市場は米国が支配的です。

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Incは、北米の経皮ドラッグデリバリーシステム市場で事業を展開している大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の経皮ドラッグデリバリーシステム市場- 主要産業力学

  • 市場促進要因
    • 慢性疾患の有病率の増加
    • 非侵襲ドラッグデリバリーデバイスへの需要の高まり
    • 薬剤の自己投与に対する高い需要
  • 市場抑制要因
    • 経皮ドラッグデリバリーシステムの副作用とリコール
  • 市場機会
    • スマートパッチと3Dプリントパッチの進歩
  • 今後の動向
    • メーカーによる戦略的取り組み
  • 影響分析

第5章 経皮ドラッグデリバリーシステム市場：北米市場分析

  • 北米の経皮ドラッグデリバリーシステム市場収益、2022年～2030年

第6章 北米の経皮ドラッグデリバリーシステム市場：タイプ別

  • 経皮パッチ
  • 経皮ゲル
  • 経皮スプレー
  • その他

第7章 北米の経皮ドラッグデリバリーシステム市場：用途別

  • 心血管疾患
  • 中枢神経系疾患
  • 疼痛管理
  • ホルモン用途
  • その他の用途

第8章 北米の経皮ドラッグデリバリーシステム市場：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第9章 北米の経皮ドラッグデリバリーシステム市場：国別分析

  • 米国
  • カナダ
  • メキシコ

第10章 経皮ドラッグデリバリーシステム市場業界情勢

  • 経皮ドラッグデリバリーシステム市場の成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第11章 企業プロファイル

  • Novartis AG
  • Johnson & Johnson
  • GSK Plc
  • Viatris Inc
  • Boehringer Ingelheim International GmbH
  • Hisamitsu Pharmaceutical Co Inc
  • Luye Pharma Group Ltd
  • Lavipharm SA
  • Purdue Pharma LP
  • UCB SA

第12章 付録

図表

List Of Tables

  • Table 1. North America Transdermal Drug Delivery System Market Segmentation
  • Table 2. US: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. US: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Canada: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Canada: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Mexico: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Recent Inorganic Growth Strategies in the Transdermal Drug Delivery System Market
  • Table 21. Recent Organic Growth Strategies in the Transdermal Drug Delivery System Market
  • Table 22. Glossary of Terms, North America Transdermal Drug Delivery System Market

List Of Figures

  • Figure 1. North America Transdermal Drug Delivery System Market Segmentation, By Country
  • Figure 2. North America Transdermal Drug Delivery System Market: Key Industry Dynamics
  • Figure 3. North America Transdermal Drug Delivery System Market: Impact Analysis of Drivers and Restraints
  • Figure 4. North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2020 - 2030
  • Figure 5. North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
  • Figure 6. Transdermal Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Matrix Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Vapor Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Transdermal Gels: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Transdermal Sprays: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 15. Cardiovascular Diseases: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Central Nervous System Disorders: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Pain Management: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Non-Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Hormonal Applications: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Testosterone Replacement: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Other Application: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • Figure 25. Hospital Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 26. Retail Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. Online Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. North America Transdermal Drug Delivery System Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 30. North America: North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
  • Figure 31. US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 32. Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 33. Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 34. Growth Strategies in the Transdermal Drug Delivery System Market
目次
Product Code: TIPRE00013277

The North America transdermal drug delivery system market is expected to grow from US$ 14,977.62 million in 2022 to US$ 20,958.37 million by 2030. It is estimated to register a CAGR of 4.3% from 2022 to 2030.

Increasing Prevalence of Chronic Diseases Drives North America Transdermal Drug Delivery System Market

Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs but conventional capsules and tablets are unable to effectively control the ailment. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.

According to the Alzheimer's association report, in 2019, Alzheimer disease was ranked sixth and in 2020 and 2021 it was ranked seventh among the leading causes of death in in the US. According to the 2023 stats by the National Institute of Health, ~6.7 million Americans (i.e., 1 in 9 people or 10.8% of the population), aged 65 and older, have Alzheimer's dementia. The percentage of people with Alzheimer's dementia increases with age. 5% of people aged 65-74, 13.1% aged 75-84, and 33.3% aged 85 and above have Alzheimer's dementia. According to the "Global Prevalence of Young-Onset Dementia" report published in 2021, the prevalence of younger-onset dementia in the US is estimated at 110 of every 100,000 people aged 30-64 years, or ~200,000 Americans in total. Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer's disease or mild-to-moderate dementia associated with Parkinson's disease. Rivastigmine and donepezil are cholinesterase inhibitors exhibiting a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. It is a small, lipophilic, and hydrophilic molecule that is chemically well-suited for transdermal delivery.

Diabetes is a life-threatening chronic disease having no specialized cure. Both types of diabetes can lead to various problems in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th edition reports, in 2021, globally 537 million adults (20-79 years) were diabetic, and the number is likely to reach 643 million by 2030 and 783 million by 2045. Exogenous insulin is usually administered subcutaneously for diabetes management. However, the recent attention toward a smart patch that delivers insulin when needed, simplifying insulin intake and activating targeted action.

Thus, the increasing incidences of chronic diseases such as cardiovascular diseases, Alzheimer's disease, and diabetes bolster the growth of the transdermal drug delivery system market.

North America Transdermal Drug Delivery System Market Overview

The North American transdermal drug delivery system market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America transdermal drug delivery system market. The growing innovations in the transdermal drug delivery systems and increasing central nervous system disorders are among the few factors projected to accelerate the growth of the North America transdermal drug delivery system market during the forecast period. Moreover, increasing R&D activities and the introduction of novel products are propelling the market for transdermal drug delivery systems. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, enhanced patient monitoring, and improved patient compliance. According to a report titled "Recent advances in transdermal drug delivery systems," published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases.

The growing trend of personalized medicines, where treatments are tailored to individual patients, has boosted the development of medical patches that offer controlled and targeted drug delivery. This customization allows for better patient outcomes and improved therapeutic efficacy. For instance, in 2020, Reddy's Laboratories launched an Authorized Generic Version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. With the growing emphasis on home healthcare and remote patient monitoring, medical patches offer a convenient solution for delivering medications and monitoring vital signs outside traditional healthcare settings. The US transdermal drug delivery system market is influenced by factors such as the increasing prevalence of chronic diseases, rising technological advancements, and growing focus on personalized medicines.

North America Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)

North America Transdermal Drug Delivery System Market Segmentation

The North America transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the North America transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the North America transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the North America transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the North America transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

Based on distribution channel, the North America transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the North America transdermal drug delivery system market in 2022.

Based on country, the North America transdermal drug delivery system market is segmented into the US, Canada, and Mexico. The US dominated the North America transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Inc are some of the leading companies operating in the North America transdermal drug delivery system market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Transdermal Drug Delivery System Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic Diseases
    • 4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
    • 4.1.3 High Demand for Self-Administration of Drugs
  • 4.2 Market Restraints
    • 4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
  • 4.3 Market Opportunities
    • 4.3.1 Advancements in Smart Patches and 3D-Printed Patches
  • 4.4 Future Trends
    • 4.4.1 Strategic Initiatives by Manufacturers
  • 4.5 Impact Analysis

5. Transdermal Drug Delivery System Market - North America Market Analysis

  • 5.1 North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 - 2030

6. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Type

  • 6.1 Overview
  • 6.2 North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
  • 6.3 Transdermal Patches
    • 6.3.1 Overview
    • 6.3.2 Transdermal Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.1 Drug-in-Adhesive Patches
        • 6.3.2.1.1 Overview
        • 6.3.2.1.2 Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.2 Matrix Patches
        • 6.3.2.2.1 Overview
        • 6.3.2.2.2 Matrix Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.3 Reservoir Membrane Patches
        • 6.3.2.3.1 Overview
        • 6.3.2.3.2 Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.4 Vapor Patches
        • 6.3.2.4.1 Overview
        • 6.3.2.4.2 Vapor Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Transdermal Gels
    • 6.4.1 Overview
    • 6.4.2 Transdermal Gels: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Transdermal Sprays
    • 6.5.1 Overview
    • 6.5.2 Transdermal Sprays: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Application

  • 7.1 Overview
  • 7.2 North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
  • 7.3 Cardiovascular Diseases
    • 7.3.1 Overview
    • 7.3.2 Cardiovascular Diseases: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Central Nervous System Disorders
    • 7.4.1 Overview
    • 7.4.2 Central Nervous System Disorders: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Pain Management
    • 7.5.1 Overview
    • 7.5.2 Pain Management: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.5.2.1 Opioid
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.5.2.2 Non-Opioid
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Non-Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Hormonal Applications
    • 7.6.1 Overview
    • 7.6.2 Hormonal Applications: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.6.2.1 Transdermal Estrogen & Progesterone Therapy
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.6.2.2 Testosterone Replacement
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Testosterone Replacement: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Other Application
    • 7.7.1 Overview
    • 7.7.2 Other Application: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 8.1 Overview
  • 8.2 North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Retail Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Online Pharmacies
    • 8.5.1 Overview
    • 8.5.2 Online Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - Country Analysis

  • 9.1 North America Transdermal Drug Delivery System Market
    • 9.1.1 North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
      • 9.1.1.1 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.1.1 Overview
        • 9.1.1.1.2 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.1.3 US: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.1.3.1 US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.1.4 US: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.1.4.1 US: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.1.4.2 US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.1.5 US: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.1.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.2.3 Canada: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.2.3.1 Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.2.4 Canada: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.2.4.1 Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.2.4.2 Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.2.5 Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.1.3 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.3.3 Mexico: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.3.3.1 Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.3.4 Mexico: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.3.4.1 Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.3.4.2 Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.3.5 Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Transdermal Drug Delivery System Market Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Transdermal Drug Delivery System Market
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Novartis AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Johnson & Johnson
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 GSK Plc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Boehringer Ingelheim International GmbH
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Hisamitsu Pharmaceutical Co Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Luye Pharma Group Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Lavipharm SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Purdue Pharma LP
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 UCB SA
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms